These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 19711210)

  • 1. Assessment of endothelial (dys)function in atrial fibrillation.
    Krishnamoorthy S; Lim SH; Lip GY
    Ann Med; 2009; 41(8):576-90. PubMed ID: 19711210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endothelium and atrial fibrillation. The prothrombotic state revisited.
    Freestone B; Lip GY
    Hamostaseologie; 2008 Oct; 28(4):207-12. PubMed ID: 18836646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of direct current cardioversion for persistent atrial fibrillation on indices of endothelial damage/dysfunction.
    Freestone B; Chong AY; Blann AD; Lip GY
    Thromb Res; 2006; 118(4):479-85. PubMed ID: 16318868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels.
    Freestone B; Chong AY; Nuttall S; Lip GY
    Thromb Res; 2008; 122(1):85-90. PubMed ID: 17996280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease.
    Jover E; Marín F; Roldán V; Montoro-García S; Valdés M; Lip GY
    Ann Med; 2013 May; 45(3):274-90. PubMed ID: 23216106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices.
    Savelieva I; Bajpai A; Camm AJ
    Ann Med; 2007; 39(5):371-91. PubMed ID: 17701479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk.
    López-Cuenca A; Marín F; Roldán V; González-Conejero R; Hernández-Romero D; Valdés M; Lip GY
    Ann Med; 2010 Dec; 42(8):562-75. PubMed ID: 20681943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation.
    Greiser M; Neuberger HR; Harks E; El-Armouche A; Boknik P; de Haan S; Verheyen F; Verheule S; Schmitz W; Ravens U; Nattel S; Allessie MA; Dobrev D; Schotten U
    J Mol Cell Cardiol; 2009 Mar; 46(3):385-94. PubMed ID: 19100271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation.
    Conway DS; Buggins P; Hughes E; Lip GY
    J Am Coll Cardiol; 2004 Jun; 43(11):2075-82. PubMed ID: 15172416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of plasma von Willebrand factor levels, an index of endothelial damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation.
    Roldán V; Marín F; García-Herola A; Lip GY
    Thromb Res; 2005; 116(4):321-5. PubMed ID: 16038717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction.
    Akar JG; Jeske W; Wilber DJ
    J Am Coll Cardiol; 2008 May; 51(18):1790-3. PubMed ID: 18452786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality and atrial fibrillation: is there a causal relationship?
    Levitt H; Coplan NL
    Rev Cardiovasc Med; 2009; 10(1):25-8. PubMed ID: 19367229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial dysfunction and pathophysiological correlates in atrial fibrillation.
    Guazzi M; Arena R
    Heart; 2009 Feb; 95(2):102-6. PubMed ID: 19109515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thromboembolism risks in atrial fibrillation].
    Babuty D; Gorin L; Zannad N; Fauchier L
    Ann Cardiol Angeiol (Paris); 2009 Dec; 58 Suppl 1():S11-3. PubMed ID: 20103170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanism and risk factors of cardiogenic thromboembolism in patients with atrial fibrillation].
    Otsuka T
    Nihon Rinsho; 2013 Jan; 71(1):36-40. PubMed ID: 23631169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis?
    Freestone B; Chong AY; Lim HS; Blann A; Lip GY
    Ann Med; 2005; 37(5):365-72. PubMed ID: 16179272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial fibrillation: pathophysiology and current therapy.
    Miyazaki S; Shah AJ; Scherr D; Haïssaguerre M
    Ann Med; 2011; 43(6):425-36. PubMed ID: 21361860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anticoagulation in atrial fibrillation].
    Binggeli C; Brunckhorst CB
    Herz; 2008 Feb; 33(1):13-9. PubMed ID: 18273573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study).
    Friberg L; Hammar N; Ringh M; Pettersson H; Rosenqvist M
    Eur Heart J; 2006 Aug; 27(16):1954-64. PubMed ID: 16847008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.